Rationale: Pathological neovascularization is a critical component of diseases such as proliferative retinopathies, cancer and rheumatoid arthritis, yet much remains to be learned about the underlying causes. Previous studies showed that vascular endothelial growth factor (VEGF)-A activates the membrane-anchored metalloproteinase ADAM17 (a disintegrin and metalloproteinase 17) in endothelial cells, thereby stimulating crosstalk between VEGF receptor 2 and extracellular signal-regulated kinase. These findings raised interesting questions about the role of ADAM17 in angiogenesis and neovascularization in vivo. Objective: The objective of this study was to inactivate ADAM17 in endothelial cells or in pericytes to determine how this affects developmental angiogenesis, pathological retinal neovascularization and heterotopic tumor growth. Methods and Results: We generated animals in which floxed ADAM17 was removed by Tie2-Cre in endothelial cells, or by smooth muscle (sm) Cre in smooth muscle cells and pericytes. There were no evident developmental defects in either conditional knockout strain, but pathological retinal neovascularization and growth of heterotopically injected tumor cells was reduced in Adam17flox/flox/Tie2-Cre mice, although not in Adam17flox/ flox/sm-Cre mice. Moreover, lack of ADAM17 in endothelial cells decreased ex vivo chord formation, and this could be largely restored by addition of the ADAM17 substrate HB-EGF (heparin-binding epidermal growth factor-like growth factor). Finally we found that ADAM17 is important for the VEGF receptor 2 stimulated processing of several receptors with known functions in endothelial cell biology. Conclusions: These results provide the first evidence for a role for ADAM17 in pathological neovascularization in vivo. Because ADAM17 does not appear to be required for normal developmental angiogenesis or vascular homeostasis, it could emerge as a good target for treatment of pathological neovascularization. (Circ Res. 2010; 106:932-940.)
also critical for epidermal growth factor (EGF) receptor (EGFR) signaling, via the proteolytic release of several ligands of the EGFR. 11 Mice lacking ADAM17 die shortly after birth with defects resembling those in animals lacking transforming growth factor ␣ (wavy whiskers and open eyes), HB-EGF (thickened and misshapen heart valves), or the EGFR. 11, 12 Further studies of ADAM17 demonstrated that it is responsible for the stimulated release of numerous additional membrane-anchored proteins, including molecules with important functions in endothelial cells, such as the VEGFR2 and Tie2. 6, 13, 14 Moreover ADAM17-dependent shedding of several of its substrates, including EGFR-ligands, can be stimulated by VEGF-A in endothelial cells. 6 The activation of ADAM17 by VEGF-A is responsible for crosstalk between the VEGFR2 and extracellular signal-regulated kinase 1/2, most likely because EGFR-ligands shed from VEGF-Astimulated endothelial cells activate the EGFR. 6 The ability of ADAM17 to release endothelial cell membrane proteins on stimulation with VEGF-A raised questions about what role ADAM17 has during developmental angiogenesis and in pathological neovascularization in adult animals. Although mice lacking ADAM17 die perinatally, most likely as a consequence of their severe heart valve defects, 11, 12 there have been no reports of defects in developmental angiogenesis in these animals. To address whether ADAM17 has a role in angiogenesis or pathological neovascularization or both, we conditionally inactivated ADAM17 in endothelial cells or in smooth muscle cells such as pericytes, and then determined how lack of ADAM17 affects two mouse models for pathological neovascularization, the oxygen induced retinopathy model for retinopathy of prematurity, and growth of heterotopically injected tumor cells. Moreover, we assessed proliferation and chord formation of endothelial cells lacking ADAM17, and evaluated the role of ADAM17 in the proteolytic release of membrane proteins with known roles in angiogenesis and pathological neovascularization.
Methods

Reagents and Cell Lines
Porcine aortic endothelial cells expressing VEGFR2/KDR (PAE/ KDR cells) and mouse embryonic fibroblasts (mEFs) lacking ADAM17 have been described previously. 6, 15 Reagents were from Sigma, unless indicated otherwise. VEGF-A and HB-EGF were from R&D Systems, and antibodies against platelet endothelial cell adhesion molecule (PECAM), NG2, endothelial NO synthase, and ␣sma were from BD Pharmingen.
Mouse Lines
To generate mice lacking ADAM17 in endothelial cells, we crossed Adam17flox/flox mice 7 with Tie2-Cre mice 16 (kindly provided by Dr. Tom Sato) or sm-Cre mice (Jackson labs; Tg(TagIn-cre) 1Her/J). Expression of Cre was monitored using Rosa26-Lac-Z reporter (R26R) mice (Jackson labs; B6.129S4-Gt(ROSA)26Sortm1Sor/J).
Oxygen-Induced Retinopathy, Heterotopic Tumor Injection, and Evaluation of Retinal Vascular Development
The analysis of postnatal retinal vascular development, the oxygeninduced retinopathy model and heterotopic injection of B16F0 melanoma cells have been described elsewhere. 17, 18 For details, see the expanded Methods section, available in the Online Data Supplement at http://circres.ahajournals.org.
Shedding Assays
Protein ectodomain shedding assays using alkaline phosphatase (AP)-tagged substrates in mouse embryonic fibroblasts and PAE/ KDR cells were performed as described. 6, 15 
Endothelial Cell Assays
Primary endothelial cells from lungs and hearts of 9 to 12-day-old mice were prepared as described. 19 Proliferation of primary endothelial cells was measured with the Celltiter proliferation assay from Promega. In vitro endothelial cell chord formation was performed using a kit from Cell Biolabs Inc (San Diego, Calif).
Immunofluorescence, Western Blot, and Fluorescence-Activated Cell-Sorting Analysis
Immunofluorescence analysis for PECAM, isolectin B4, NG2 and ␣sma, Western blot analysis of retina extracts and fluorescence-activated cell-sorting (FACS) analysis was performed as described. 17, 18, 20 
Results
Characterization of Adam17flox/flox/Tie2-Cre Mice
To assess whether ADAM17 has a role in pathological neovascularization, we generated mice carrying floxed alleles of ADAM17 and the Cre-recombinase expressed in endothelial cells under the Tie-2 promoter 16 (see Methods for details). Matings of Adam17flox/flox/Tie2-Cre with Adam17flox/flox mice gave rise to offspring of the expected Mendelian ratio (48% Adam17flox/flox, 52% Adam17flox/flox/Tie2-Cre, nϭ327). The efficient excision of ADAM17 in endothelial cells isolated from Adam17flox/flox/Tie2-Cre mice was confirmed by Western blot analysis ( Figure 1A ). Adam17flox/ flox/Tie2-Cre mice appeared normal during routine handling, and a complete necropsy and histopathologic evaluation did not uncover any evident defects compared to littermate controls (Adam17flox/flox) (see Methods). Moreover, stain- ing of histological sections of the aorta or a vessel in the heart with antibodies against the endothelial cell marker PECAM or the pericyte marker ␣sma did not reveal differences in the appearance or patterning of the stained structures from Adam17flox/flox/Tie2-Cre mice compared to Adam17flox/ flox controls (Online Figure I) . To determine whether the absence of ADAM17 affected the distribution of Tie2-Cre expressing cells, we performed X-gal staining on sections of the aorta, heart and lung of mice carrying Tie2-Cre and the ubiquitously expressed Cre-dependent Lac-Z reporter (Ro-sa26 Lac-Z reporter (R26R)) in the presence of either one or both floxed alleles of ADAM17 (Adam17flox/flox/Tie2-Cre/ R26R or Adam17flox/ϩ/Tie2-Cre/R26R). No difference in the distribution of X-gal-stained cells in the presence or absence of ADAM17 was observed (Online Figure II) . Moreover, the presence or absence of Tie2-Cre in Adam17flox/flox mice also did not affect the development of the retinal vascular tree with respect to its size relative to that of the retina as well as the appearance of the vessels at postnatal day 6 ( Figure 1B through 1D ). Thus conditional inactivation of ADAM17 in endothelial cells did not lead to evident defects in mouse development or adult homeostasis, or in the development of the retinal vasculature.
Non-standard Abbreviations and Acronyms
Conditional Inactivation of ADAM17 in Endothelial Cells Reduces Oxygen-Induced Retinopathy
To assess whether ADAM17 contributes to pathological retinal neovascularization, we subjected Adam17flox/flox/ Tie2-Cre mice and Adam17flox/flox littermate controls to a model for retinopathy of prematurity, the oxygen induced retinopathy (OIR) model, (see Methods). At the completion of the OIR experiment at day p17, we found a significantly larger central avascular area in Adam17flox/flox/Tie2-Cre mice compared to controls (Figure 2A and 2B). Moreover, there was a significant decrease in the number of endothelial cells that traversed the internal limiting membrane toward the vitreous body in Adam17flox/flox/Tie2-Cre mice compared to controls ( Figure 2C ). X-gal staining of retinas from Adam17flox/flox/Tie2-Cre/R26R mice corroborated that Tie2-Cre was effective in endothelial cells throughout the retinal vasculature (Online Figure III , A) and in pathological neovascular tufts (Online Figure III, B ). When we subjected mice carrying one wild type and one floxed allele of ADAM17 in the presence or absence of Tie2-Cre to the OIR model (Adam17flox/ϩ/Tie2-Cre mice or Adam17flox/ϩ controls), we found that Tie2-Cre did not significantly affect the outcome of this model when ADAM17 was present. This control corroborates that the decreased response of Adam17flox/flox/Tie2-Cre mice to the OIR model is attributable to deletion of floxed ADAM17, but not the expression of Tie2-Cre (Online Figure III, C ). An immunofluorescence analysis of the expression of the endothelial cell marker isolectin B4 or the pericyte marker NG2 in pathological neovascular tufts showed a similar staining pattern in the tufts that developed in Adam17flox/flox/Tie2-Cre mice compared to Adam17flox/flox controls (Online Figure 
Heterotopic Tumor Injection Model
Because the results of the OIR model suggested that ADAM17 in endothelial cells has a role in pathological neovascularization, we subjected Adam17flox/flox/Tie2-Cre mice and Adam17flox/flox controls to a heterotopic tumor injection model, which provides information on the contribution of host-derived factors and cells, such as endothelial cells, to tumor growth. After subcutaneous injection of B16F0 melanoma cells, tumor growth was monitored for two to three weeks. In three separate experiments, tumor growth was significantly reduced in Adam17flox/flox/Tie2-Cre mice compared to controls ( Figure 3A ). Sections of tumors from Adam17flox/flox/Tie2-Cre mice and controls did not display significant differences in the distribution or appearance of PECAM-stained tumor vessels ( Figure 3B and 3C). When we compared heterotopic tumor growth in mice with one wild type allele of ADAM17 in the presence or absence of Tie2-Cre (Adam17flox/ϩ/Tie2-Cre or Adam17flox/ϩ mice), we found no difference in tumor growth, arguing against an effect of the Tie2-Cre alone on this heterotopic tumor model (Online Figure IV) . These experiments are consistent with a role for ADAM17 in pathological neovascularization or in generation of host-derived factors from endothelial cells that contribute to tumor growth.
Inactivation of ADAM17 in ␣SMA-Expressing Cells Does Not Detectably Affect Pathological Neovascularization
Pericytes represent another major cell type in the vasculature besides endothelial cells. To determine whether ADAM17 in pericytes is important for angiogenesis or pathological neovascularization, we generated mice carrying floxed ADAM17 and a Cre-recombinase expressed under the control of the ␣sma promoter (Adam17flox/flox/sm-Cre mice). The Adam17flox/flox/sm-Cre animals were born at the expected Mendelian ratio (52% Adam17flox/flox/sm-Cre, 48% Adam17flox/flox, nϭ101) and developed normally, with no evident pathological changes compared to littermate Adam17flox/flox controls (see Methods). A Western blot analysis of vascular smooth muscle cells cultured from aortae of Adam17flox/flox/sm-Cre mice and Adam17flox/flox controls by the explant method (see Methods) corroborated the efficient excision of floxed ADAM17 by sm-Cre in vascular smooth muscle cells (Online Figure V) . Moreover, an analysis of several tissues and organs containing ␣sma-expressing cells (aorta, heart, small intestine) did not uncover any evident defects in Adam17flox/flox/sm-Cre mice compared to Adam17flox/flox controls (Online Figure VI, A) . To determine whether the presence or absence of ADAM17 affected the distribution of sm-Cre expressing cells, we performed X-gal staining on sections of aortae and hearts of mice carrying sm-Cre and the Rosa26 lac-Z reporter in the presence of either one or both floxed alleles of ADAM17 (Adam17flox/flox/sm-Cre/R26R or Adam17flox/؉/sm-Cre/ R26R). No difference in the distribution of X-gal stained cells in the presence or absence of ADAM17 was observed (Online Figure VI, B ). In addition, there was no difference in the development of the retinal vascular tree at P6 in Adam17flox/ flox mice in the presence or absence of sm-Cre (Online Figure  VII, A and B) . After exposure to the OIR model, the size of the central avascular area (Online Figure VIII, A and B ) and the number of endothelial cells that crossed the internal limiting membrane were comparable between Adam17flox/ flox/sm-Cre mice and Adam17flox/flox controls (Online Figure VIII, C; note that because of the relatively low numbers of endothelial cells in Adam17flox/flox controls, we cannot rule out subtle effects of the lack of ADAM17 in ␣smaexpressing cells in the OIR model). X-gal staining of retinal sections from sm-Cre/R26R mice corroborated the expression of sm-Cre in neovascular tufts (Online Figure VIII, D) . Finally, heterotopically injected B16F0 melanoma cells gave rise to tumors of similar weight in Adam17flox/flox/sm-Cre mice and Adam17flox/flox controls (Online Figure IX) . Thus, we found no evidence for a contribution of ADAM17 in ␣sma-expressing cells to developmental retinal angiogenesis, pathological retinal neovascularization or to a heterotopic tumor model.
ADAM17 Has a Role in Chord Formation of Endothelial Cells
To explore the contribution of ADAM17 to ex vivo endothelial cell assays, we isolated endothelial cells from Adam17flox/flox/Tie2-Cre mice and Adam17flox/flox controls, and assessed proliferation and chord formation in the presence or absence of VEGF-A or HB-EGF. We found no difference in proliferation of Adam17flox/flox/Tie2-Cre endothelial cells compared to controls ( Figure 4A ). However, there was a substantial decrease in chord formation in endothelial cells from Adam17flox/flox/Tie2-Cre mice that were treated with or without VEGF-A compared to controls ( Figure 4B ). This defect in chord formation in Adam17flox/flox/Tie2-Cre endothelial cells could be largely rescued by addition of soluble HB-EGF, an EGFR-ligand that is a substrate of ADAM17 ( Figure 4B ).
ADAM17 Is Involved in Shedding a Variety of Membrane Proteins With Roles in Angiogenesis and Neovascularization
Previous studies have implicated ADAM17 in the proteolytic release of several membrane-anchored proteins, including molecules with known roles in angiogenesis, such as VEGFR2, ICAM-1, Tie2 and CD40. 6 To test whether ADAM17 is involved in the shedding of additional membrane-proteins with known functions in endothelial cell biology, we transfected AP-tagged VE-cadherin, vascular cell adhesion molecule (V-CAM), EphB4, extracellular matrix metalloproteinase inducer (EMMPRIN), insulin-like growth factor receptor (IGFR)1, or PECAM into wild-type or Adam17 Ϫ/Ϫ mouse embryonic fibroblasts (mEFs). We found a phorbol 12-myristate 13-acetate (PMA)-dependent increase in the shedding of the ectodomains of these membrane proteins in wild type mEFs, which could be prevented by incubation with the hydroxamic acid-type metalloproteinase inhibitor marimastat ( Figure 5A ). The PMA-stimulated component for each of these substrates was abolished in Adam17 Ϫ/Ϫ mEFs, and for VE-cadherin, V-CAM and EMMPRIN, constitutive shedding was also reduced. Moreover, we found that shedding of the ADAM17 substrates VE-cadherin, V-CAM, EphB4, EMMPRIN, IGFR1 or PE-CAM from pig aortic endothelial cells expressing the VEGFR2 (PAE-KDR cells) was stimulated by addition of VEGF-A, whereas shedding of the ADAM10 substrates EGF and betacellulin was not ( Figure 5B ). Finally, FACS analysis showed an approximately 40% increase in PECAM on the surface of endothelial cells from Adam17flox/flox/Tie2-Cre mice compared to Adam17flox/flox controls ( Figure 5C ). This was further corroborated by Western blot analysis of the sorted cells, where increased levels of PECAM and Tie2 correlated with strongly decreased ADAM17 in Adam17flox/ flox/Tie2-Cre endothelial cells compared to Adam17flox/flox controls ( Figure 5D ). These results confirm that ADAM17 regulates the levels of endogenous PECAM and Tie2 in primary endothelial cells.
Discussion
The main objective of this study was to evaluate the role of the membrane-anchored metalloproteinase ADAM17 in angiogenesis and pathological neovascularization. We found that inactivation of ADAM17 in endothelial cells had no evident effect on developmental angiogenesis, whereas it significantly reduced pathological neovascularization in a mouse model for retinopathy of prematurity, and affected the growth of heterotopically injected tumor cells. Moreover, chord formation in ADAM17-deficient endothelial cells was strongly reduced compared to controls, and could be partially rescued by addition of the EGFR-ligand and ADAM17 substrate HB-EGF, which is expressed on endothelial cells. 12, 15, 21 On the other hand, inactivation of ADAM17 in ␣sma-expressing cells had no evident effect on retinal angiogenesis, the outcome of the OIR model or on the growth of heterotopically injected tumor cells. The observation that the inactivation of ADAM17 in endothelial cells reduces pathological neovascularization provides the first direct evidence for a role of this cellular sheddase in endothelial cells in vivo. Moreover, the ability of HB-EGF to largely rescue the decreased chord formation of ADAM17-deficient endothelial cells suggests that the underlying mechanism involves EGFR-signaling stimulated by HB-EGF or related EGFR-ligands released by ADAM17 from endothelial cells. This is consistent with previous studies that have implicated HB-EGF and its proteolytic release in angiogenesis, although the identity of the responsible enzyme was not determined. [22] [23] [24] [25] [26] Moreover, our finding that HB-EGF partially rescues chord formation in ADAM17deficient endothelial cells, whereas VEGF does not, suggests that HB-EGF affects endothelial cells directly instead of via production of VEGF, as proposed by Hollborn et al. 27 The apparently normal pericyte ensheathment of endothelial cells in the absence of ADAM17 suggests that release of HB-EGF by ADAM17 is not essential for this process. 21 However, addition of HB-EGF to ADAM17-deficient endothelial cells did not completely restore chord formation, so other substrates of ADAM17 that are important for its role in neovascularization are likely to exist. Indeed, we also show that ADAM17 is able to process several receptors with important functions in endothelial cells, and that their shedding can be activated by VEGF (also see elsewhere 6 ), and so defects in the processing of one or more additional substrates of ADAM17 could also be partially responsible for its role in neovascularization. In principle, processing could inactivate membrane receptors, although ectodomain shedding can also activate receptors such as Notch. 28 Given the substantial number of currently known substrates for ADAM17 and the dearth of information on how shedding affects the function of individual receptors, it is currently not possible to predict which additional shedding events besides the release of HB-EGF account for the role of ADAM17 in neovascularization. To address this question, it will be necessary to study how the processing of individual receptors affects their function in cell-based assays and in vivo, for example by "knocking in" mutations that inactivate their cleavage site. Nevertheless, the ability of HB-EGF to largely rescue chord formation in ADAM17-deficient endothelial cells suggests that activation of the EGFR is an important component of the mechanism underlying the role of ADAM17 in neovascularization. So, even though ADAM17 can, in principle, process many membrane proteins on the surface of endothelial cells, our results suggest that HB-EGF and possibly also other EGFR-ligands that are shed by ADAM17 are likely to be the functionally dominant substrates of ADAM17 in the context of pathological neovascularization. Perhaps the increase in surface levels of membrane proteins such as Tie2 and PECAM in ADAM17deficient endothelial cells is less relevant to angiogenesis and neovascularization than the regulation of the bio-availability of EGFR-ligands, which is also the functionally dominant activity of ADAM17 during mouse development. ADAM17 has also been implicated in processing Notch. 29 However, mice lacking Notch1 and 4 die very early during embryogenesis, 28, 30 and ADAM10-deficient mice resemble mice that lack Notch1 and 4, 31 whereas mice lacking ADAM17 die at birth. 11 Therefore ADAM17 does not appear to be essential for activating Notch during mouse development. Finally, it should be noted that ADAMs are modular proteins that also contain a disintegrin domain, cysteine-rich region and a cytoplasmic domain, so it is conceivable that functions of these ancillary domains that are not related to the catalytic activity of ADAM17 could also be important for its role in pathological neovascularization. 13, 14 Taken together, these results suggest that ADAM17 could be an attractive target for treatment of proliferative retinopathies and potentially also for preventing other diseases that depend on pathological neovascularization, such as cancer and rheumatoid arthritis. An appealing feature of ADAM17 in the context of pathological neovascularization is that it does not have an evident role in normal developmental angiogenesis or in the maintenance of the vasculature in adult mice. ADAM17 is currently considered as a target for treatment of rheumatoid arthritis because of its role in generating soluble TNF␣, 32 and for treatment of ErbB-dependent tumors, because of its critical role in activating EGFR-ligands. 33 Interestingly, TIMP3, which is tightly associated with ADAM17 in extracts from endothelial cells and inhibits ADAM17 and other metalloproteinases, 34 -36 reduces pathological neovascularization in an OIR mouse model. 37 Moreover, abnormal choroidal neovascularization as well as an increased angiogenic response has been observed in Figure 5 . Evaluation of the role of ADAM17 in ectodomain shedding of membrane proteins with roles in angiogenesis. A, To identify potential ADAM17 substrates in endothelial cells, AP-tagged fusion proteins for membrane proteins with roles in angiogenesis were transfected into wild type or Adam17 Ϫ/Ϫ mouse embryonic fibroblasts (mEFs). Shedding of VE-cadherin, V-CAM, EphB4, EMMPRIN, IGFR1, and PECAM from transfected wild-type mouse embryonic fibroblasts was stimulated by short-term treatment with 25 ng/mL PMA, which activates ADAM17, but not ADAM10. 15, 20, 40 The PMA-dependent and constitutive shedding of VE-cadherin, V-CAM, and EMMPRIN was reduced in Adam17 Ϫ/Ϫ mEFs, as was the PMA-dependent but not the constitutive shedding of IGFR1 and EphB4, corroborating that ADAM17 is responsible for the stimulated shedding of these proteins in mEFs. B, When the AP-tagged receptors were transfected into porcine aortic endothelial cells expressing VEGFR2/KDR (PAE/KDR cells), treatment with VEGF-A, which activates ADAM17, but not ADAM10, 6 increased the shedding of VE-cadherin, V-CAM, EphB4, EMMPRIN, IGFR1, and PECAM, but not of the ADAM10 substrates EGF and betacellulin (BTC) (WMW test, *Pϭ0.04, **Pϭ0.02). C, FACS analysis of primary endothelial cells gated for the endothelial cell markers endothelial NO synthase and ICAM2 showed increased PECAM levels (41.2Ϯ6.4%) on cells from Adam17flox/flox/Tie2-Cre mice compared to controls. D, Western blot of FACS-sorted ICAM-positive primary endothelial cells shows increased levels of PECAM/CD31 (top left blot) and Tie2 (top right blot) and strongly decreased levels of ADAM17 (bottom blot, same as top left blot, stripped and reprobed with anti-ADAM17) in cells from Adam17flox/flox/Tie2-Cre mice compared to Adam17flox/flox controls (see Methods for details).
Timp3 Ϫ/Ϫ mice. 38 Because conditional inactivation of ADAM17 in endothelial cells has a similar effect in the mouse OIR model as intravitreal injection of TIMP3expressing adeno-associated viral vectors, 37 ADAM17 is likely a functionally relevant target of TIMP3 during pathological neovascularization.
In summary, the conditional inactivation of ADAM17 in endothelial cells provides the first evidence for a critical role of ADAM17 during pathological neovascularization in mice in vivo. Moreover, the ability of HB-EGF to rescue chord formation in endothelial cells lacking ADAM17 is consistent with the previously established essential role for ADAM17 in activating ligands of the EGFR, including HB-EGF. [11] [12] [13] 15, 39 Based on these results, it will now be interesting to test how conditional inactivation of the EGFR in endothelial cells or pericytes affects the outcome of the models for pathological neovascularization presented here. Our results raise the possibility that selective inhibition of ADAM17 could be beneficial for treatment of pathological neovascularization in the context of proliferative retinopathies, rheumatoid arthritis, and cancer.
